We appreciate Dr. Hanno's insightful comments on our paper. They were objective and accurate. The treatment of interstitial cystitis/bladder pain syndrome with daily low-dose sildenafil was based on our clinical investigation and basic science research. Since the first introduction of sildenafil in China, we have continuously observed that it could improve sexual function and simultaneously relieve dyspareunia and pelvic area pain in patients with these combined symptoms. However, the evidence of the sildenafil's efficacy on treating interstitial cystitis was limited. After the accumulation of documents suggested that phosphodiesterase type 5 inhibitors can improve lower urinary tract symptoms, as well as considering the positive results of our basic study,1'2 the clinical trial was designed.
展开▼
